Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas

被引:0
|
作者
P Legembre
P Moreau
S Daburon
J-F Moreau
J-L Taupin
机构
[1] Laboratoire d'Immunologie,
[2] CNRS UMR 5540,undefined
[3] Université de Bordeaux 2,undefined
[4] bâtiment 1b,undefined
[5] Laboratoire de Biogenèse Membranaire,undefined
[6] CNRS UMR 5544,undefined
[7] Université de Bordeaux 2,undefined
来源
关键词
GPI; Fas; apoptosis; microdomains;
D O I
暂无
中图分类号
学科分类号
摘要
FasL and TRAIL are apoptotic ligands of the TNF-like cytokines family, acting via activation of the transmembrane death domain containing receptors Fas for FasL, and DR4 or DR5 for TRAIL. A glycosylphosphatidylinositol-linked TRAIL receptor called DcR1 behaves as a decoy receptor inhibiting TRAIL-mediated cell death in several cellular systems. We engineered and stably expressed a chimeric GPI-linked Fas receptor (Fas-GPI) in T-lymphocyte cell lines constitutively expressing functional transmembrane Fas. Surprisingly, despite lacking the death domain region of functional Fas, Fas-GPI was able to significantly increase Fas-mediated cell death triggered by membrane bound or soluble FasL, whereas engagement of Fas-GPI alone did not trigger apoptosis. This potentiating effect, but not transmembrane Fas activation, was selectively inhibited by protein kinase C activation with phorbol esters, demonstrating that Fas-GPI activated a specific synergistic signal transduction pathway. Fas-GPI and transmembrane Fas were localized in distinct membrane compartments, since Fas-GPI, but not transmembrane Fas, was found in the glycolipid-rich membrane microdomains. These results suggest that apoptosis induced by members of this ligand/receptors family may be differentially modulated through other and parallel signalling pathways.
引用
收藏
页码:329 / 339
页数:10
相关论文
共 50 条
  • [21] JNK activation is not required for Fas-mediated apoptosis
    Low, W
    Smith, A
    Ashworth, A
    Collins, M
    ONCOGENE, 1999, 18 (25) : 3737 - 3741
  • [22] Thyroid carcinoma cells and Fas-mediated apoptosis
    Mitsiades, CS
    Mitsiades, N
    THYROID, 2005, 15 (02) : 178 - 179
  • [23] JNK activation is not required for Fas-mediated apoptosis
    Walter Low
    Anna Smith
    Alan Ashworth
    Mary Collins
    Oncogene, 1999, 18 : 3737 - 3741
  • [24] Fas-mediated apoptosis in mouse osteoclasts.
    Wu, X
    McKenna, M
    Feng, X
    McDonald, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S271 - S271
  • [25] Fas-mediated apoptosis in cultured human eosinophils
    Druilhe, A
    Cai, ZZ
    Haile, S
    Chouaib, S
    Pretolani, M
    BLOOD, 1996, 87 (07) : 2822 - 2830
  • [26] Somatic mutation in the absence of fas-mediated apoptosis
    Panoutsakopoulou, V
    Schwaber, J
    FASEB JOURNAL, 1996, 10 (06): : 976 - 976
  • [27] Fas-mediated apoptosis in accelerated graft arteriosclerosis
    Moldovan N.I.
    Qian Z.
    Chen Y.
    Dong C.
    Ying A.
    Hruban R.H.
    Flavahan N.A.
    Baldwin III W.M.
    Sanfilippo F.
    Goldschmidt-Clermont P.J.
    Angiogenesis, 1998, 2 (3) : 245 - 254
  • [28] Functional roles of sphingomyelin in Fas-mediated apoptosis
    Miyaji, M
    Okazaki, T
    Bloom, ET
    Amakawa, R
    Fukuhara, S
    Umehara, H
    FASEB JOURNAL, 2004, 18 (04): : A41 - A41
  • [29] Fas-mediated apoptosis in tumor formation and defense
    Hug, H
    BIOLOGICAL CHEMISTRY, 1997, 378 (12) : 1405 - 1412
  • [30] Fas-mediated apoptosis in acute alcoholic hepatitis
    Tagami, A
    Ohnishi, H
    Moriwaki, H
    Phillips, M
    Hughes, RD
    HEPATO-GASTROENTEROLOGY, 2003, 50 (50) : 443 - 448